Synapse - Alison Moskowitz

Results (355)

Accelerated total lymphoid irradiation-containing salvage regimen for patients with refractory and relapsed Hodgkin lymphoma: 20 years of experience

Journal Article

Rimner, A.; Lovie, S.; Hsu, M.; Chelius, M.; Zhang, Z.; Chau, K.; Moskowitz, A. J.; Matasar, M.; Moskowitz, C. H.; Yahalom, J.
International Journal of Radiation Oncology, Biology, Physics (2017)

Fulltext@MSK | Save

Preliminary results from a phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Meeting Abstract

Herrera, A. F.; Bartlett, N. L.; Ramchandren, R.; Vose, J. M.; Moskowitz, A. J.; Feldman, T. A.; LaCasce, A. S.; Ansell, S. M.; Moskowitz, C. H.; Fenton, K.; more...
Blood (2016)

Fulltext@MSK | Save

Metabolic tumor volume to predict event free survival in patients with relapsed/refractory HL treated with brentuximab vedotin-based salvage therapy

Meeting Abstract

Gavane, S. C.; Ito, K.; Moskowitz, C. H.; Moskowitz, A. J.; Schoder, H.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs)

Meeting Abstract

Armand, P.; Brody, J.; Barr, P. M.; Shustov, A. R.; Moskowitz, A. J.; Kline, J. P.; Savage, K. J.; Kuruvilla, J.; Josephson, N. C.; Zinzani, P. L.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Interim PET evaluation by Deauville criteria is an effective risk stratification tool in PTCL

Meeting Abstract

Mehta-Shah, N.; Ito, K.; Bantilan, K. S.; Moskowitz, A. J.; Sauter, C. S.; Horwitz, S. M.; Schoder, H.
Blood (2016)

Fulltext@MSK | Save

Pembrolizumab for treatment of relapsed/refractory mycosis fungoides and Sezary syndrome: Clinical efficacy in a CITN multicenter phase 2 study

Meeting Abstract

Khodadoust, M.; Rook, A. H.; Porcu, P.; Foss, F. M.; Moskowitz, A. J.; Shustov, A. R.; Shanbhag, S.; Sokol, L.; Shine, R.; Fling, S. P.; more...
Blood (2016)

Fulltext@MSK | Save

The outcome of patients with primary refractory or relapsed peripheral T-cell lymphoma: Analysis of 1020 cases registered in the prospective T-cell project

Meeting Abstract

Bellei, M.; Foss, F. M.; Horwitz, S. M.; Marcheselli, L.; Kim, W. S.; Cabrera, M. E.; Dlouhy, I.; Nagler, A.; Advani, R. H.; Pesce, E.; more...
Blood (2016)

Fulltext@MSK | Save

A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039)

Meeting Abstract

Ansell, S.; Gutierrez, M. E.; Shipp, M. A.; Gladstone, D.; Moskowitz, A.; Borello, I.; Popa-Mckiver, M.; Farsaci, B.; Zhu, L.; Lesokhin, A. M.; more...
Blood (2016)

Fulltext@MSK | Save

A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas

Meeting Abstract

Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; more...
Blood (2016)

Fulltext@MSK | Save

Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era

Meeting Abstract

Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
Blood (2016)

Fulltext@MSK | Save